Eisai Offloads AkaRx To Tighten Therapeutic Focus
This article was originally published in PharmAsia News
Eisai is divesting its AkaRx operation and assets, acquired in 2010, to a health care-focused US private equity group in a move the Japanese firm says will free up resources for its two main therapeutic areas.
You may also be interested in...
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
German mRNA specialist choses Singapore as its first regional hub in Asia Pacific, where it also plans to build a manufacturing site to support the global supply of both vaccines and therapeutics and a regional “rapid response” capability for future pandemics.
In this week's podcast version of Five Must-Know Things, hear about IP waivers for coronavirus vaccines; launch records for Pfizer’s COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.